Prana Biotechnology (PRAN) is up after it says it secured a key PBT2 patent in Japan. The Japanese Patent Office has granted a composition of matter patent for PRAN's lead clinical asset, PBT2 and other selected 8-Hydroxyquinoline compounds in Japan.
The patent also covers pharmaceutical compositions containing PBT2 and selected 8-hydroxyquinoline compounds and the use of the compounds to treat Alzheimer's Disease.
